Fidelity International
NTLA icon

Fidelity International’s Intellia Therapeutics NTLA Stock Holding History

Fidelity International’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-83,926
Closed -$597K – 1009
2025
Q1 		$597K Sell
83,926
-75,745
-47% -$765K ﹤0.01% 768
2024
Q4 		$1.86M Buy
159,671
+140,608
+738% +$2.19M ﹤0.01% 688
2024
Q3 		$392K Buy
19,063
+598
+3% +$13.8K ﹤0.01% 798
2024
Q2 		$413K Buy
18,465
+8,841
+92% +$211K ﹤0.01% 768
2024
Q1 		$265K Buy
9,624
+681
+8% +$18.9K ﹤0.01% 790
2023
Q4 		$273K Buy
+8,943
New +$257K ﹤0.01% 758
2023
Q2 		– Sell
-80,000
Closed -$2.98M – 837
2023
Q1 		$2.98M Sell
80,000
-115
-0.1% -$4.51K ﹤0.01% 634
2022
Q4 		$2.8M Buy
+80,115
New +$3.81M ﹤0.01% 642

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity International's NTLA Position: Q2 2025 in Review

Fidelity International sold out of Intellia Therapeutics (NTLA) in Q2 2025, closing a stake of 83,926 shares — an estimated $597K sold.

Fidelity International first reported a position in NTLA in Q4 2022 and held it in 8 quarters. The position peaked at $2.98M in Q1 2023. 280 funds tracked by Wall St. Rank hold NTLA as of Q2 2025.

  • Fidelity International reported no remaining Intellia Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Fidelity International sold 83,926 Intellia Therapeutics shares in Q2 2025, an estimated $597K.
  • Fidelity International first reported a position in Intellia Therapeutics in Q4 2022 and held it in 8 quarters.
  • Fidelity International's Intellia Therapeutics position peaked at $2.98M in Q1 2023.
  • 280 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2025.

Based on Fidelity International's 13F filing for Q2 2025, filed 14 Aug 2025.